{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "DTIL", "name": "Precision BioSciences, Inc.", "url": "https://frontierpicks.com/dossiers/DTIL/", "json_url": "https://frontierpicks.com/dossiers/DTIL.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Precision BioSciences’ hepatitis B gene-editing thesis needs replicated liver-biopsy results by year-end 2026. The case succeeds if additional patients show cccDNA reduction without treatment-limiting safety findings before a weekly close below $6.50 invalidates it.", "invalidation_trigger": "A weekly close below $6.50 ends the setup at its previously published research boundary; contrary additional biopsy findings, a clinical hold, or year-end 2026 passing without replication also defeats the clinical thesis.", "catalyst_date": null, "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "rare-disease-gene-therapy", "precision-biotech-therapeutics", "binary-catalyst-biotech" ], "tags": [], "sources": [], "notes": [ "Runway 'through 2028' is stated as resting on cash plus availability of the at-the-market facility (Q2 release, 2026-08-06) — equity issuance is part of the stated plan.", "Reported net loss includes non-cash warrant-liability remeasurement ($11.9M in Q2 2026) that widens when the share price rises; EPS versus consensus can be non-operational.", "No product revenue: Q2 2026 revenue was $0 against a compiled FY2026 consensus revenue of $13.48M.", "Sell-side coverage is thin — 5 analysts, compiled average target $29.4 versus a $20 median and a $60 high (stockanalysis.com, retrieved 2026-09-05)." ], "body_markdown": "## Current Thesis\n\nPrecision BioSciences’ hepatitis B gene-editing thesis depends on the year-end 2026 update reproducing its initial liver-biopsy result in additional patients before the market breaches the published $6.50 weekly-close boundary. The company’s 2026-08-06 update retained that clinical timetable; no subsequent clinical result was identified in the company release index reviewed on 2026-09-13. [Company releases](https://investor.precisionbiosciences.com/press-releases)\n\nThe narrative is maturing — the mechanism headline dates to 2026-05-27, while the 2026-09-11 reference close was $7.17, below the $7.47 close recorded on 2026-09-04. This is an inference about the dated sequence of news and prices; participation data are missing. Replicated biopsy findings would challenge that classification by supplying new clinical evidence.\n\n## Bull Case\n\n- **Direct evidence in liver tissue.** On 2026-05-27, Precision reported a 1-log reduction in covalently closed circular DNA (cccDNA)-derived transcripts after two 0.4 mg/kg doses and described less than 1% of cccDNA remaining. These are company-reported measurements supporting the proposed mechanism; the biopsy sample is too small to establish reproducibility. [Clinical release](https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-new-and-late-breaking-pbgene-hbv)\n- **Blood markers support biological activity.** At the 2026-05-04 cutoff, the company reported loss of detectable pregenomic RNA (pgRNA) in six patients with detectable pretreatment levels and hepatitis B surface antigen (HBsAg) declines in 15 patients. These observations do not establish durable cure after existing antiviral treatment stops. [2026-05-27 results](https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-new-and-late-breaking-pbgene-hbv)\n- **Another program entered clinical testing.** Precision announced first dosing in the FUNCTION-DMD trial for Duchenne muscular dystrophy on 2026-08-24. That establishes clinical execution for PBGENE-DMD; it supplies no evidence yet of patient benefit. [Company announcement index](https://investor.precisionbiosciences.com/press-releases)\n\n## Bear Case\n\n- **Safety requires fuller qualification.** The 2026-05-27 release reported no dose-limiting toxicities, but also reported severe hypotension and two serious adverse events in a patient receiving 0.8 mg/kg, one treatment-related. Slower infusions and increased steroids were introduced; absence of dose-limiting toxicity does not mean absence of serious harm. [Clinical safety disclosure](https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-new-and-late-breaking-pbgene-hbv)\n- **Runway includes prospective equity funding.** The 2026-08-06 financial update reported $112.4 million in cash, equivalents and restricted cash at 2026-06-30. Management’s runway through 2028 included availability under its at-the-market equity facility; that financing assumption is distinct from cash already reported.\n- **Clinical replication remains unresolved.** The 2026-05-27 biopsy headline rests on the initial patient result described above. Failure to reproduce cccDNA reduction in additional patients at the guided year-end update would invalidate the clinical extension of that finding.\n\n## Setup & Price Structure\n\nThe supplied adjusted market series records a $7.17 close on 2026-09-11, 22.7% below its $9.28 52-week high, alongside a positive 17.5% three-month price change. Its 14-period relative strength index (RSI) was 9.6 on that date. The snapshot shows weak recent momentum within a positive three-month comparison; it does not establish a rebound.\n\nThe $6.50 weekly-close threshold remains the research boundary published on 2026-09-05. The available snapshot does not independently establish that level as traded support. Moving-average values, volume, short interest and dated retail-participation measures are missing, so crowding cannot be determined. The equity facility described on 2026-08-06 establishes potential share supply, without demonstrating subsequent issuance into strength.\n\n## Catalyst Calendar (next 30 days)\n\nFor 2026-09-13 through 2026-10-13, no company-confirmed catalyst date was identified in the available announcements or event calendar. The calendar’s latest listed 2026 investor presentation was on 2026-06-03; that listing does not rule out an unscheduled announcement. [Company event calendar](https://investor.precisionbiosciences.com/events-and-presentations)\n\n- **~2026-12-31, timing placeholder:** The 2026-08-06 update guided additional PBGENE-HBV clinical results to year-end 2026. December 31 represents the end of that guidance window, not an announced presentation date. Additional biopsies are the test of replication; an update without them would leave the thesis unconfirmed. [Quarterly update](https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-reports-second-quarter-2026-financial)\n\n## What Would Change Our Mind\n\nLoss of the published market boundary ends this setup: a weekly close below $6.50 constitutes price invalidation. Clinical confirmation requires additional patients showing cccDNA reduction by the end of the company’s 2026 guidance window without a treatment-limiting safety finding. Contrary biopsy results, a clinical hold, or the year-end window passing without replication would defeat that stated case.\n\nThe evidence supports low conviction because the initial biopsy sample cannot establish reproducibility, the 2026-05-27 disclosure contains serious safety events, and the 2026-09-11 price snapshot shows weak recent momentum.\n\n## Correlation Notes\n\nThis remains a single-company clinical setup. The 2026-09-13 research context supplies no established peer cluster or matched return series, so a measured correlation with gene-editing equities cannot be stated. The 2026-08-24 start of Precision’s own Duchenne trial broadens its clinical exposure, but does not independently validate the hepatitis B result.", "first_seen": "2026-09-03", "last_analyzed": "2026-09-18T06:03:42+00:00", "last_synthesized": "2026-09-13", "last_update_source": "research_universe", "license": "Content © FrontierPicks. Cite the canonical URL." }